---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000030"
form_type: "8-K/A"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:11:17.240357+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere Q1 2025 net product sales $75.9M, FILSPARI U.S. sales up 182% YoY; net loss narrows to $41.2M

## Summary
- FILSPARI U.S. net product sales $55.9M in Q1 2025, up 182% YoY; 703 new patient start forms received.
- Net loss of $41.2M ($0.47/share) vs $136.1M ($1.76) in Q1 2024; non-GAAP net loss $16.9M ($0.19).
- sNDA for full approval of FILSPARI in FSGS submitted March 2025; FDA acceptance decision expected May 2025.
- European Commission converted FILSPARI to standard MA for IgAN; expects $17.5M milestone from CSL Vifor in Q2 2025.
- Cash, cash equivalents, and marketable securities $322.2M as of March 31, 2025.

## SEC filing metadata
- accession: 0001438533-25-000030
- form_type: 8-K/A
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000030/0001438533-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000030/tvtx-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000030
- JSON: https://secwatch.observer/filing/0001438533-25-000030.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.